We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

174 hedge funds and large institutions have $3.38B invested in Neurocrine Biosciences in 2015 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 56 increasing their positions, 55 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

331% more first-time investments, than exits

New positions opened: 56 | Existing positions closed: 13

101% more capital invested

Capital invested by funds: $1.68B → $3.38B (+$1.7B)

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

46% more call options, than puts

Call options by funds: $32.5M | Put options by funds: $22.3M

31% more funds holding

Funds holding: 133 → 174 (+41)

2% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 55

Holders
174
Holders Change
+41
Holders Change %
+30.83%
% of All Funds
4.64%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.11%
New
56
Increased
56
Reduced
55
Closed
13
Calls
$32.5M
Puts
$22.3M
Net Calls
+$10.2M
Net Calls Change
+$45.3M

Top Buyers

Rank Fund Capital Flow
1
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$81.9M
2
PC
PointState Capital
New York
+$67.4M
3
Invesco
Invesco
Georgia
+$60.3M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$56.6M
5
EAM
Eagle Asset Management
Florida
+$46.4M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$26M
2
ACH
ArrowMark Colorado Holdings
Colorado
-$25.5M
3
Franklin Resources
Franklin Resources
California
-$20.4M
4
TCM
Tekla Capital Management
Massachusetts
-$17.9M
5
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans
Minnesota
-$15.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
Prudential Financial
76
Prudential Financial
New Jersey
$3.49M +$7.15K +200 +0.2%
ProShare Advisors
77
ProShare Advisors
Maryland
$3.37M +$656K +18,338 +28%
PAM
78
Paradigm Asset Management
New York
$3.2M +$479K +13,400 +20%
NFA
79
Nationwide Fund Advisors
Ohio
$3.07M +$704K +19,682 +34%
SFM
80
Sphera Funds Management
Israel
$2.98M +$894K +25,000 +50%
MAA
81
Managed Account Advisors
New Jersey
$2.82M +$1.81M +50,662 +248%
AIG
82
American International Group
New York
$2.65M -$823K -23,011 -26%
Dimensional Fund Advisors
83
Dimensional Fund Advisors
Texas
$2.55M +$2.29M +64,100 New
State Board of Administration of Florida Retirement System
84
State Board of Administration of Florida Retirement System
Florida
$2.54M -$229K -6,391 -9%
VFA
85
Virtus Fund Advisers
Connecticut
$2.36M -$198K -5,524 -9%
Two Sigma Investments
86
Two Sigma Investments
New York
$2.34M +$2.11M +58,898 New
DBG
87
De Burlo Group
Massachusetts
$2.32M -$107K -3,000 -5%
3NC
88
300 North Capital
California
$2.23M -$86.9K -2,429 -4%
BlackRock
89
BlackRock
New York
$2.21M -$652K -18,237 -25%
ARTA
90
A.R.T. Advisors
New York
$2.07M +$1.87M +52,243 New
American Century Companies
91
American Century Companies
Missouri
$2.06M -$339K -9,487 -15%
ACM
92
Atika Capital Management
New York
$2.03M +$1.29M +36,200 +241%
IHM
93
Iguana Healthcare Management
New York
$1.99M +$1.79M +50,000 New
MOACM
94
Mutual of America Capital Management
New York
$1.97M +$1.77M +49,577 New
SO
95
STRS Ohio
Ohio
$1.75M -$368K -10,300 -19%
CSS
96
Cubist Systematic Strategies
Connecticut
$1.69M +$1.07M +29,997 +240%
JMPWA
97
JP Morgan Private Wealth Advisors
California
$1.68M -$348K -9,740 -19%
AA
98
ALPS Advisors
Colorado
$1.65M +$1.48M +41,481 New
VOYA Investment Management
99
VOYA Investment Management
Georgia
$1.6M – – –
ACPU
100
Arrowgrass Capital Partners (US)
Delaware
$1.59M +$1.43M +40,000 New
2 3
4
5 6

NBIX Hedge Fund Activity: Q1 2015 in Review

174 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q1 2015, worth a combined $3.38B — up 101% from $1.68B a quarter earlier.

Buyers outnumbered sellers: 56 funds opened new NBIX positions and 13 closed out — a net gain of 43 holders — while 56 added to existing stakes and 55 trimmed.

The largest buyer was Westfield Capital Management, opening a new position worth an estimated $81.9M. The largest seller was Citadel Advisors, cutting an estimated $26M.

  • 174 institutional investors held Neurocrine Biosciences (NBIX) as of Q1 2015, up from 133 in Q4 2014.
  • Funds reported $3.38B of Neurocrine Biosciences stock for Q1 2015, up 101% quarter-over-quarter.
  • 56 funds opened new Neurocrine Biosciences positions in Q1 2015 and 13 closed out, a net change of +43 holders.
  • The largest Neurocrine Biosciences buyer in Q1 2015 was Westfield Capital Management, an estimated $81.9M added.
  • The largest Neurocrine Biosciences seller in Q1 2015 was Citadel Advisors, an estimated $26M sold.

Based on aggregated 13F filings for Q1 2015.